GICS 2021 Jury's Still Out on Trifluridine/Tipiracil Plus Bev in mCRC First-line trifluridine/tipiracil plus bevacizumab offered a slight survival benefit over capecitabine plus bevacizumab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results